Press releases | Deinove

04.05.2020

Alexis RIDEAU appointed Deputy Chief Executive Officer of DEINOVE with the ambition to strengthen the Company's strategy for innovation and partnerships

• Alexis RIDEAU has recognized experience in the development, negotiation and implementation of strategic partnerships in the life sciences...

30.03.2020

The current health, economic and financial crisis creates too much uncertainty to enter into a long-term full partnership around a complete...

20.01.2020

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

26.09.2019

Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections...

09.07.2019

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

28.03.2019

Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium...

18.02.2019

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

21.11.2018

The equity line funding set up in December 2014 expired. It has enabled DEINOVE to raise €9.4 million net in a flexible, optimized manner...

27.09.2018

Cash position: +€9.9m at June 30, 2018 compared to +€4.9m at December 31, 2017 thanks to the reinforcement of shareholders' equity Half-...

15.06.2018

Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia and Japan. The...